&w=3840&q=100)
Oyo to expand to 300 cities by FY26, eyes doubling booking revenue
IPO-bound global travel tech platform Oyo on Friday said it plans to accelerate company-serviced hotel expansion in FY26. It expects to double the booking revenue from its company-serviced properties from 22 to 44 per cent in this period, while also increasing its presence from 124 cities to over 300 cities across India.
Currently, the platform has more than 1,300 company-serviced hotels in the country, including Townhouse, Capital O, Palette and Townhouse Oak-branded hotels, the popular mid-segment brands for the company. It is eyeing 1,800 company-serviced hotels by FY26, compared to around 900 in FY25.
Oyo is focusing on leisure cities, pilgrimage destinations and business corridors, where demand remains strong for expansion. A few cities in the pipeline include Mohali, Faridabad and Jalandhar in the north; Cuttack, Asansol and Darjeeling in the east; Mangalore, Kollam, Port Blair and Kasaragod in the south; and Bhilwara, Vapi, Junagarh and Jalgaon in the west, the company added.
Speaking on the expansion plan, Varun Jain, Chief Operating Officer of the company, said: 'The programme is in line with Oyo's strategic focus for 2025 for the India market, which aims to drive profitability by enhancing the overall guest experience. These hotels record a higher customer rating of 4.6, compared to the overall average of 4.0. The occupancy rate of these hotels is also 2.7 times higher than other hotels. Their consistent focus on quality service also drives a repeat customer rate that is 1.3 times higher than the rest. The superior ratings reflect better service standards, well-maintained facilities and a seamless guest experience, which results in stronger guest loyalty and repeat stays in our hotels.'
Oyo initially introduced company-serviced hotels in FY23. During that period, they contributed less than 2 per cent of its booking revenue.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
Business Standard
an hour ago
- Business Standard
Torrent Pharma to acquire JB Pharma from KKR at ₹25,689 cr valuation
In one of the largest pharma deals in the domestic market in recent years, Ahmedabad-based Torrent Pharmaceuticals will acquire a controlling stake in investment firm KKR-backed JB Chemicals and Pharmaceuticals (known as JB Pharma) at an equity valuation of ₹25,689 crore, which will be followed by the merger of the two entities. The deal will be executed in two phases — acquisition of the 46.39 per cent stake held by KKR in JB Pharma at ₹1,600 per share, amounting to ₹11,917 crore, followed by a mandatory open offer to acquire up to 26 per cent of JB Pharma shares from public shareholders at ₹1,639.18 per share. 'In addition to the above, Torrent has also expressed its intent to acquire up to 2.8 per cent of equity shares from certain employees of JB Pharma at the same price per share as KKR,' the company said in a statement on Sunday. The next step in the deal will be a merger between Torrent Pharma and JB Pharma through a scheme of arrangement, under which every shareholder holding 100 shares in JB Pharma will receive 51 shares of Torrent Pharma. The boards of directors of both companies have approved this arrangement. KKR had acquired 54 per cent of JB Pharma in July 2020 from the promoters and founders, the Mody family, for approximately ₹3,100 crore (or ₹745 per share). It sold a part of its stake in March this year through block deals for ₹1,459.8 crore. KKR has earned more than five times on its investment, with around 36 per cent gross IRR. For instance, Torrent Pharma has previously indicated plans to increase its medical representative (MR) strength by 23 per cent by the end of FY26, and the acquisition can aid in manpower augmentation. Torrent Pharma holds a 3.74 per cent share in the domestic market (according to Pharmarack, May 2025), while JB Pharma commands a 1.12 per cent share. Further, consolidation in key international markets is expected to offer greater scalability. Samir Mehta, executive chairman of Torrent Pharma, said they want to build on JB Pharma's heritage and platform for the future. 'Torrent's deep India presence and JB Pharma's fast-growing India business, combined with the CDMO and international footprint, offer immense potential to scale both revenue and profitability. This strategic alignment furthers our goal of strengthening our presence in the Indian pharma market and builds a larger diversified global presence. Moreover, the CDMO platform provides a new long-term avenue of growth for Torrent.' Torrent has previously taken the inorganic route to grow its business and enter newer segments — in 2013, it acquired Elder Pharma's India-branded business; followed by the dermaceutical business of Zyg Pharma in 2015 and the API plant of Glochem Industries in 2016. Among other major deals, it bought the India-branded business of Unichem in 2017. Its last major acquisition was of skin-care products from Curatio Healthcare in 2022. Torrent Pharma is a highly domestic-focused company, drawing around 55 per cent of its consolidated revenues from the domestic formulations business. India sales grew by 13 per cent in FY25 to ₹6,393 crore. While the company has been outperforming industry growth in the domestic market, it is also planning to increase MR strength by 23 per cent by FY26-end. Torrent has a strong presence in the cardiovascular, gastrointestinal and neurology segments. JB too has prominent cardiac and gastro brands like Cilacar, Metrogyl and Rantac. Torrent is also working on launching GLP-1 products as a day-one launch in FY26. Analysts expect a 15 per cent sales CAGR in domestic formulations for Torrent Pharma over FY25–27. Gaurav Trehan, co-head of Asia Pacific and head of Asia Pacific private equity at KKR, and CEO of KKR India, said: 'JB Pharma's transformation under our stewardship is a testament to KKR's ability to scale high-quality companies.' Nikhil Chopra, chief executive officer and whole-time director of JB Pharma, pointed out that over the past five years, the company has emerged as one of India's fastest-growing pharmaceutical players. 'We have built a strong foundation to deliver market-leading growth, as well as consistent improvement in profitability in the medium and long term. As we now enter a new chapter alongside Torrent Pharmaceuticals, we are confident that the combined strengths of our organisations will unlock greater opportunities to enhance healthcare access across our markets,' Chopra said. JB Pharma posted 12 per cent revenue growth in FY25 to ₹3,918 crore, while its EBITDA rose 16 per cent to ₹1,087 crore, and PAT increased 19 per cent to ₹660 crore. Notably, KKR Private equity has invested $2 billion in India in 2024 and recently invested $600 million in Manipal Group via its private credit arm.
Hindustan Times
2 days ago
- Hindustan Times
Startup Mantra: Giving nurses wings
Pune: After spending 10 years with his earlier venture upGrad, Mayank Kumar left in October 2024 to start another company — BorderPlus — with his co-founder Ayush Mathur (who was earlier with OYO). The genesis of BorderPlus began when Mayank was in Germany and happened to visit an old age home. Lack of healthcare professionals at a foreign country triggered Ayush to set up his second startup BorderPlus that aims to meet the increasing demand for skilled nurses in Europe to begin with. (AP (PIC FOR REPRESENTATION)) 'I noticed there that despite having capacity they could absorb maybe 70%-80% elderly people. The reason? They lacked staff that could care for them. This was the case in most of the old age homes there. While their population was growing old, they did not have enough young, able-bodied people to look after them. Also, about 90% of the residents were women. And besides having someone to care for them, they wanted a person who they could talk to, someone to share their day with. And, unfortunately, this was missing.' 'To address this demographic crisis – this huge shortfall of caregivers, in such homes, Germany was planning to hire thousands of Indian nurses over the next few years.' And so, Mayank's entrepreneurial mind began to work in overdrive. 'This was something we noticed in countries around the world. They were struggling to find skilled workers, especially in healthcare, logistics, and construction. A key driver of this shortage is the aging population in many developed nations. In Japan, nearly 30% of the population is over 65. Germany isn't far behind, with 22% of its population in the same age bracket. As older populations grow and birth rates decline, the pressure on essential services, especially healthcare, is increasing sharply. At the same time, India has a large, young, and trained talent pool. But most people don't have access to the right support systems to take their skills global,' he said. This was an opportunity knocking at the door. Mayank Kumar (HT) Mayank set out to build a solution for this need. He met with several stakeholders across countries- hospital recruiters, healthcare administrators, and policymakers. 'What we consistently heard was that the talent gap wasn't just about skills or degrees. It was about language proficiency and real-world readiness.' Mayank understood that to serve the need in those countries he had do more than just send out blue-collar workers on the next plane to Germany. 'There's no shortage of qualified professionals in India. But without strong language training, cultural preparation, and the ability to meet local standards, most would never get access to global opportunities.' And so, he got down to fill that gap in their qualification. 'That's when we realised that if we could integrate a finishing school with language training, career support, and employer demand and layer it with technology for scale and credibility, we could build something truly transformative. A platform that doesn't just move people, but prepares them to stay, grow, and thrive in their new environments. Getting down to work Simply getting blue-collar workers jobs abroad was not the goal was obvious. They had to be trained like in a finishing school. They had to have fluency in the foreign language, understand their customs and culture, get assistance with various legal procedures, be able to crack the visa interviews. BorderPlus helps people build global careers, not just get jobs abroad. Mayank said, 'Finishing school helps train participants in German language and healthcare-specific communication, prepare for cultural and professional expectations, help with documents, interviews, and visa paperwork, and connect to employers abroad.' With his tech skills and upGrad experience, Mayank devised an AI tool that can teach nurses German in 750 to 800 hours. 'If they put in five to six hours every weekday they can learn the language in seven months to about a year. Our AI-powered training platform supports learners with personalised feedback, real-time pronunciation correction, and self-paced practice modules. It complements the finishing school experience and makes sure candidates can build fluency and confidence even outside the classroom.' The programme fee for nurses is ₹ 2 lakh and the amount is reimbursed either through a BorderPlus scholarship or relocation support. 'Our revenue model is employer-based, meaning we only earn when a hospital or recruiter successfully hires someone we've trained,' he said. BorderPlus charges employers ₹ 4 lakh to ₹ 12 lakh per worker placed. Building the platform Since both the founders come with prior entrepreneurial background, assembling a strong early team and raising capital was not their biggest challenge. Mayank, 'What mattered more was to have clarity - a clear understanding of the problem, the systems we needed to build, and how to solve it meaningfully at scale. The real work now is focused execution, integrating training, tech, and compliance into one seamless experience for both candidates and employers. We're building for trust and long-term impact, and that takes time. We're not just trying to scale, we're trying to solve the problem in a way that actually works for everyone involved. We're still building it and there's a lot more work ahead.' The money story Up until now Mayank and his co-founder Ayush started with founder capital of ₹ 1 crore and a few small grants, keeping it lean and intentional. In February 2025, they raised $7 million in their first institutional round. Owl Ventures led the round, with support from investors like Binny Bansal, Ritesh Agarwal, Mithun Sacheti, Apoorva Patni, and Aakash Chaudhary. 'The funds are going into scaling our finishing school model, building AI-led tools like a language bot, expanding to new sectors, and setting up more training hubs across India and beyond.' Ayush Mathur (HT) Each candidate contributes roughly 40%–50% margin after accounting for costs. 'The current focus is on optimising delivery while maintaining quality and compliance.' In their first batch they enrolled 150 nurses who will complete their course in October-November this year. 'Even before our batch closure we are seeing our nurses getting placed.' The country in focus is Germany but plans are afoot to cater to Japan, the UK, Canada, Europe, GCC. Competition Mayank is not unduly concerned about competition because he knows that at the moment there aren't many players who provide the kind of services that they do. 'There are players who focus on either recruitment or training, but not many who do both in a structured, end-to-end way. What sets us apart is our full-stack approach. We don't just find people jobs, we train them, prepare them, and support them all the way. It's about outcomes, not just placements.' Plans to scale Their training hubs are in Pune and Kochi. This 'finishing school' model takes a candidate from language and soft skills to culture and documentation. It runs through both physical hubs and digital tools like AI-led language bots and modular training content. Parallelly, they are working closely with employers, hospitals and governments in their destination countries. The big picture According to Mayank, 'The global demand for skilled professionals, especially in healthcare, is not just large, it's also accelerating. The World Health Organization projects a global shortfall of 4.5 million nurses by 2030. Countries like Germany, Italy, Japan, and the UK are actively expanding visa routes and relaxing norms to bring in foreign talent, with India emerging as a preferred source due to the strong reputation of its nurses. India has a growing, young workforce, but most lack access to structured global pathways. That's the gap we're solving. 'We're building structured global careers backed by training, technology, and trust. Our goal is to create 42 mobility routes across sectors, beginning with healthcare and soon expanding into other high-demand fields like logistics and construction. 'Our model is vertically integrated from language training and cultural preparation to documentation, placement, and post-arrival support. For destination countries, that means better-prepared, longer-retaining talent. For candidates, it means a smoother, more supported journey to global opportunity,' he said. Future plans BorderPlus has seen a 20%-30% increase in demand for nurses since its launch in January this year. 'We're setting up more hubs across Delhi NCR, the North East, and South India, and expanding quickly through a franchise model. We're also scaling in the Philippines and Brazil, and actively training 150+ nurses there right now. The goal is to train 100,000 nurses in the next few months. And we're also exploring strategic partnerships and acquisitions to grow faster in key regions.' Mayank and Ayush have set their sights across the globe. Time will tell how this will play out for India's blue-collared workers.
Time of India
2 days ago
- Time of India
Trumps drop 'Made in the USA' claim for new phone and a debate ensues: How to define 'made'?
By Bernard Condon NEW YORK: When the Trump family unveiled a new phone before a giant American flag at its headquarters earlier this month, the pitch was simple and succinct, packed with pure patriotism: "Made in the U.S.A." The Trumps are apparently having second thoughts. How about "proudly American"? Those are the two words that have replaced the "Made in the USA" pitch that just a few days ago appeared on the website where customers can pre-order the so-called T-1 gold-toned phones with an American flag etched on the back. Elsewhere on the site, other vague terms are now being used, describing the $499 phone as boasting an "American-Proud Design" and "brought to life right here in the U.S.A." The Federal Trade Commission requires that items labeled " Made in USA " be "all or virtually all" produced in the U.S. and several firms have been sued over misusing the term. The Trump Organization has not explained the change and has not responded to a request for comment. Neither did an outside public relations firm handling the Trumps' mobile phone business , including a request to confirm a statement made to another media outlet. "T1 phones are proudly being made in America," said Trump Mobile spokesman Chris Walker, according to USA Today. "Speculation to the contrary is simply inaccurate." The language change on the website was first reported by the news site The Verge. An expert on cell phone technology, IDC analyst Francisco Jeronimo, said he's not surprised the Trump family has dropped the "Made in the USA" label because it's nearly impossible to build one here given the higher cost and lack of infrastructure to do so. But, of course, you can claim to do it. "Whether it is possible or not to build this phone in the US depends on what you consider 'build,'" Jeronimo said. "If it's a question of assembling components and targeting small volumes, I suppose it's somehow possible. You can always get the components from China and assemble them by hand somewhere." "You're going to have phones that are made right here in the United States of America," said Trump's son Eric to Fox News recently, adding, "It's about time we bring products back to our great country." The Trump family has flown the American flag before with Trump-branded products of suspicious origin, including its "God Bless the USA" Bibles, which an Associated Press investigation last year showed were printed in China. The Trump phone is part of a bigger family mobile business plan designed to tap into MAGA enthusiasm for the president. The two sons running the business, Eric and Don Jr., announced earlier this month that they would offer mobile phone plans for $47.45 a month, a reference to their father's status as the 45th and 47th president. The call center, they said, will be in the U.S., too. "You're not calling up call centers in Bangladesh," Eric Trump said on Fox News. "We're doing it out of St. Louis, Missouri." The new service has been blasted by government ethics experts for a conflict of interest, given that President Donald Trump oversees the Federal Communications Commission that regulates the business and is investigating phone service companies that are now Trump Mobile rivals. Trump has also threatened to punish cell phone maker Apple, now a direct competitor, threatening to slap 25% tariffs on devices because of its plans to make most of its U.S. iPhones in India.
